Globeimmune Cm shares had a trading volume of 9,006 by the end of trading on Tuesday. Shares saw a steep increase in trading volume of 106.84% over the normal average daily volume.
The company is now unchanged by 0.00% since yesterday’s close of 0.590. The company’s P/E ratio is N/A and the market cap of the company is 3.39M. As of the last earnings report the EPS was $-0.39 with 5.75M shares now outstanding.
GlobeImmune, Inc., launched on June 5, 2002, is a biopharmaceutical company. The Company is focused on developing products for the treatment of cancer and infectious diseases based on its Tarmogen platform. The Business’s segment is the business of developing and commercializing various biopharmaceutical products. The Company has approximately three Tarmogen product candidates in clinical evaluation for infectious disease and multiple cancer indications. The Business’s infectious disease product candidates include GS-4774, which is in Phase II for the treatment of chronic hepatitis B infection; GI-19000, which is in the preclinical stage of development for the treatment of tuberculosis; GI-2010, which is in the preclinical stage of development for the treatment of Human immunodeficiency virus (HIV), and GI-18000, which is in the preclinical stage of development for the treatment of Chronic hepatitis D infection. The Business’s oncology product candidates include GI-6207, which is in Phase II for the treatment of medullary thyroid cancer; GI-6301, which is in Phase II for the treatment of chordoma, and GI-4000, which is in Phase IIb for the treatment of Resected pancreas cancer, and in Phase II for the treatment of Non-small cell lung cancer and colorectal cancer..